An established Idaho business executive in the solar parts manufacturing industry, Steve Verschoor has a strong interest in health and wellness. Living with stage three melanoma, Steve Verschoor is presently taking part in a clinical trial centered on a serious form of skin cancer.
A recent American Journal of Public Health report brought focus to the success of new therapies targeting metastatic disease in significantly decreasing cutaneous melanoma mortality rates. According to researchers at the New York University Langone Health and Perlmutter Cancer Center, the 2013 to 2016 period represented the largest drop ever in skin cancer related deaths.
The 17.9 percent decrease in mortality had to do with new targeted medication regimens. It reversed a 30-year trend of consistently rising rates of melanoma-related deaths. This provides hope to physicians and researchers who are trying to improve the well-being of patients who would otherwise receive a negative prognosis. The targeted therapies provided are described as providing a “backbone” of how skin cancer will be treated in the future.
Steve is proud to be participating in his 2nd clinical trail. Unfortunately, he was provided a placebo in the first trial and the disease returned. Following a 3rd surgery, Steve began participating in a 2nd clinical trial to ascertain the benefit of adjuvant vs neoadjuvant Pembrolizumab treatment.
A recent American Journal of Public Health report brought focus to the success of new therapies targeting metastatic disease in significantly decreasing cutaneous melanoma mortality rates. According to researchers at the New York University Langone Health and Perlmutter Cancer Center, the 2013 to 2016 period represented the largest drop ever in skin cancer related deaths.
The 17.9 percent decrease in mortality had to do with new targeted medication regimens. It reversed a 30-year trend of consistently rising rates of melanoma-related deaths. This provides hope to physicians and researchers who are trying to improve the well-being of patients who would otherwise receive a negative prognosis. The targeted therapies provided are described as providing a “backbone” of how skin cancer will be treated in the future.
Steve is proud to be participating in his 2nd clinical trail. Unfortunately, he was provided a placebo in the first trial and the disease returned. Following a 3rd surgery, Steve began participating in a 2nd clinical trial to ascertain the benefit of adjuvant vs neoadjuvant Pembrolizumab treatment.
